Stay updated with breaking news from Px203 . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Specialty pharmaceutical company Knight Therapeutics Inc. (GUD.TO) announced Thursday it has entered into an exclusive license agreement with Amneal Pharmaceuticals, Inc.
Shares of Amneal Pharmaceuticals, Inc. (AMRX) are trading down on Wednesday morning after the company announced that the FDA sought additional information on the New Drug Application for IPX203 to treat Parkinson's disease.